Cargando…

QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications

PURPOSE: To investigate the prevalence and risk factors of acquired long QT syndrome (LQTS) on admission to a general Intensive Care Unit (ICU), and to assess the risk of LQTS associated with prescribed medications. METHODS: Prospective observational, cross-sectional study approved by the Institutio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Flávia Medeiros, Silva, Eliane Pereira, Martins, Rand Randall, Oliveira, Antonio Gouveia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999273/
https://www.ncbi.nlm.nih.gov/pubmed/29898002
http://dx.doi.org/10.1371/journal.pone.0199028
_version_ 1783331396098457600
author Fernandes, Flávia Medeiros
Silva, Eliane Pereira
Martins, Rand Randall
Oliveira, Antonio Gouveia
author_facet Fernandes, Flávia Medeiros
Silva, Eliane Pereira
Martins, Rand Randall
Oliveira, Antonio Gouveia
author_sort Fernandes, Flávia Medeiros
collection PubMed
description PURPOSE: To investigate the prevalence and risk factors of acquired long QT syndrome (LQTS) on admission to a general Intensive Care Unit (ICU), and to assess the risk of LQTS associated with prescribed medications. METHODS: Prospective observational, cross-sectional study approved by the Institutional Review Board. Between May 2014 and July 2016, 412 patients >18 years-old consecutively admitted to the ICU of a university hospital were included. LQTS was defined as a QT interval on the admission electrocardiogram corrected using Bazett’s formula (QTc) >460 ms for men and >470 ms for women. All medications administered within 24 hours before admission were recorded. Logistic regression was used. RESULTS: LQTS prevalence was 27.9%. In LQTS patients, 70.4% had ≥ 1 LQTS-inducing drug prescribed in the 24 hours prior to ICU admission versus 70.4% in non-LQTS patients (p = 0.99). Bradycardia and Charlson morbidity index score are independent risk factors for LQTS. Haloperidol (OR 4.416), amiodarone (OR 2.509) and furosemide (OR 1.895) were associated with LQTS, as well as another drug not yet described, namely clopidogrel (OR 2.241). CONCLUSIONS: The LQTS is highly prevalent in critically ill patients, ICU patients are often admitted with LQTS-inducing medications, and patients with slow heart rate or with high Charlson comorbidity index should be evaluated for LQTS.
format Online
Article
Text
id pubmed-5999273
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59992732018-06-21 QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications Fernandes, Flávia Medeiros Silva, Eliane Pereira Martins, Rand Randall Oliveira, Antonio Gouveia PLoS One Research Article PURPOSE: To investigate the prevalence and risk factors of acquired long QT syndrome (LQTS) on admission to a general Intensive Care Unit (ICU), and to assess the risk of LQTS associated with prescribed medications. METHODS: Prospective observational, cross-sectional study approved by the Institutional Review Board. Between May 2014 and July 2016, 412 patients >18 years-old consecutively admitted to the ICU of a university hospital were included. LQTS was defined as a QT interval on the admission electrocardiogram corrected using Bazett’s formula (QTc) >460 ms for men and >470 ms for women. All medications administered within 24 hours before admission were recorded. Logistic regression was used. RESULTS: LQTS prevalence was 27.9%. In LQTS patients, 70.4% had ≥ 1 LQTS-inducing drug prescribed in the 24 hours prior to ICU admission versus 70.4% in non-LQTS patients (p = 0.99). Bradycardia and Charlson morbidity index score are independent risk factors for LQTS. Haloperidol (OR 4.416), amiodarone (OR 2.509) and furosemide (OR 1.895) were associated with LQTS, as well as another drug not yet described, namely clopidogrel (OR 2.241). CONCLUSIONS: The LQTS is highly prevalent in critically ill patients, ICU patients are often admitted with LQTS-inducing medications, and patients with slow heart rate or with high Charlson comorbidity index should be evaluated for LQTS. Public Library of Science 2018-06-13 /pmc/articles/PMC5999273/ /pubmed/29898002 http://dx.doi.org/10.1371/journal.pone.0199028 Text en © 2018 Fernandes et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fernandes, Flávia Medeiros
Silva, Eliane Pereira
Martins, Rand Randall
Oliveira, Antonio Gouveia
QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications
title QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications
title_full QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications
title_fullStr QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications
title_full_unstemmed QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications
title_short QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications
title_sort qtc interval prolongation in critically ill patients: prevalence, risk factors and associated medications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999273/
https://www.ncbi.nlm.nih.gov/pubmed/29898002
http://dx.doi.org/10.1371/journal.pone.0199028
work_keys_str_mv AT fernandesflaviamedeiros qtcintervalprolongationincriticallyillpatientsprevalenceriskfactorsandassociatedmedications
AT silvaelianepereira qtcintervalprolongationincriticallyillpatientsprevalenceriskfactorsandassociatedmedications
AT martinsrandrandall qtcintervalprolongationincriticallyillpatientsprevalenceriskfactorsandassociatedmedications
AT oliveiraantoniogouveia qtcintervalprolongationincriticallyillpatientsprevalenceriskfactorsandassociatedmedications